دورية أكاديمية
The role of E2F2 in cancer progression and its value as a therapeutic target.
| العنوان: | The role of E2F2 in cancer progression and its value as a therapeutic target. |
|---|---|
| المؤلفون: | Gao Y; Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China., Qiao X; Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Liu Z; Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China., Zhang W; Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 May 14; Vol. 15, pp. 1397303. Date of Electronic Publication: 2024 May 14 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Neoplasms*/metabolism , Neoplasms*/pathology , Neoplasms*/genetics , E2F2 Transcription Factor*/metabolism , E2F2 Transcription Factor*/genetics , Disease Progression*, Humans ; Animals ; Gene Expression Regulation, Neoplastic ; Molecular Targeted Therapy ; Cell Proliferation |
| مستخلص: | The E2F family of transcription factors plays a crucial role in the regulation of cell cycle progression and cell proliferation. Accumulative evidence indicates that aberrant expression or activation of E2F2 is a common phenomenon in malignances. E2F2 has emerged as a key player in the development and progression of various types of tumors. A wealth of research has substantiated that E2F2 could contribute to the enhancement of tumor cell proliferation, angiogenesis, and invasiveness. Moreover, E2F2 exerts its influence on a myriad of cellular processes by engaging with a spectrum of auxiliary factors and downstream targets, including apoptosis and DNA repair. The dysregulation of E2F2 in the context of carcinogenesis may be attributable to a multitude of mechanisms, which encompass modifications in upstream regulatory elements or epigenetic alterations. This review explores the function of E2F2 in cancer progression and both established and emerging therapeutic strategies aiming at targeting this oncogenic pathway, while also providing a strong basis for further research on the biological function and clinical applications of E2F2. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Gao, Qiao, Liu and Zhang.) |
| References: | Mol Carcinog. 2010 Feb;49(2):152-6. (PMID: 19798698) J Cancer. 2022 Jan 1;13(2):653-668. (PMID: 35069909) CA Cancer J Clin. 2022 Nov;72(6):524-541. (PMID: 36190501) Int J Cancer. 2009 May 1;124(9):2077-81. (PMID: 19142864) J Cell Biochem. 2018 Nov;119(10):8317-8324. (PMID: 29932246) Oncol Lett. 2019 Jan;17(1):571-577. (PMID: 30655803) Cell Physiol Biochem. 2018;51(5):2324-2340. (PMID: 30537738) Front Oncol. 2021 Jul 06;11:677111. (PMID: 34295816) Oncogenesis. 2016 May 30;5(5):e229. (PMID: 27239961) Cell Growth Differ. 2002 May;13(5):215-25. (PMID: 12065245) Neoplasia. 2022 Feb;24(2):86-97. (PMID: 34954451) Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15400-5. (PMID: 17881568) Eur Rev Med Pharmacol Sci. 2017 May;21(9):2150-2156. (PMID: 28537669) EBioMedicine. 2022 Dec;86:104353. (PMID: 36375317) PLoS One. 2010 Apr 14;5(4):e10147. (PMID: 20418948) PeerJ. 2020 Feb 19;8:e8562. (PMID: 32117628) Phytomedicine. 2023 Jan;109:154565. (PMID: 36610125) Cell Cycle. 2023 Feb;22(3):347-360. (PMID: 36281526) Mol Med Rep. 2015 Jul;12(1):1016-22. (PMID: 25816091) J Cell Mol Med. 2021 Jan;25(2):1178-1189. (PMID: 33342041) Prostate. 2010 Feb 1;70(2):135-46. (PMID: 19784964) FASEB J. 2017 Nov;31(11):4821-4831. (PMID: 28739643) BMC Cancer. 2020 Oct 28;20(1):1037. (PMID: 33115417) Cell Signal. 2021 Aug;84:110014. (PMID: 33894314) Cancer Manag Res. 2020 Dec 21;12:13033-13042. (PMID: 33376397) Bioinformatics. 2014 Nov 1;30(21):3036-43. (PMID: 25028721) Breast Cancer. 2020 Jan;27(1):147-158. (PMID: 31410735) Mol Ther Nucleic Acids. 2021 Apr 24;25:37-52. (PMID: 34168917) Oncogene. 2001 Nov 29;20(55):7935-44. (PMID: 11753676) J Biol Chem. 2006 Nov 24;281(47):36124-31. (PMID: 17008321) Oncotarget. 2016 Jun 14;7(24):36577-36589. (PMID: 27174918) Biochem Biophys Res Commun. 2008 May 23;370(1):145-8. (PMID: 18355447) Breast Cancer Res. 2013 Jun 20;15(3):R51. (PMID: 23809258) Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6359-63. (PMID: 8022787) Oncotarget. 2016 May 31;7(22):32628-40. (PMID: 27081696) Oncol Lett. 2014 Oct;8(4):1487-1491. (PMID: 25202354) Cancers (Basel). 2022 Oct 10;14(19):. (PMID: 36230876) FEBS Lett. 2012 Nov 2;586(21):3831-9. (PMID: 22999819) Int J Gen Med. 2021 Nov 18;14:8463-8472. (PMID: 34824545) Cancer Biol Ther. 2006 Jul;5(7):771-6. (PMID: 16721044) Oncol Lett. 2018 Jun;15(6):9216-9230. (PMID: 29844824) Carcinogenesis. 2008 Jan;29(1):194-201. (PMID: 17916908) Genes Dev. 2002 Jan 15;16(2):245-56. (PMID: 11799067) Cell Signal. 2014 May;26(5):1075-81. (PMID: 24440307) Aging (Albany NY). 2018 May 11;10(5):973-987. (PMID: 29754146) Sci Rep. 2020 Oct 21;10(1):17948. (PMID: 33087787) Mol Cell Biol. 2003 May;23(9):3287-304. (PMID: 12697828) J Physiol Biochem. 2016 Dec;72(4):733-744. (PMID: 27520092) Exp Ther Med. 2018 Sep;16(3):2696-2702. (PMID: 30210611) Mol Cell Biol. 1996 Apr;16(4):1436-49. (PMID: 8657117) Aging (Albany NY). 2021 Apr 21;13(10):13626-13643. (PMID: 34091441) Cancer Res. 2011 Mar 1;71(5):1924-32. (PMID: 21245101) Int J Genomics. 2022 Sep 20;2022:6303996. (PMID: 36249712) Biomed Res Int. 2018 May 14;2018:3842753. (PMID: 29862267) Int J Clin Exp Pathol. 2015 Sep 01;8(9):10545-54. (PMID: 26617764) Oncogene. 2003 Aug 7;22(32):4943-52. (PMID: 12902977) J Cell Sci. 1996 Jul;109 ( Pt 7):1717-26. (PMID: 8832394) Mol Ther. 2021 Mar 3;29(3):1226-1238. (PMID: 33221435) CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525) Int J Oncol. 2001 Feb;18(2):343-7. (PMID: 11172602) Int J Clin Exp Pathol. 2020 Apr 01;13(4):711-720. (PMID: 32355519) Oncotarget. 2015 Nov 10;6(35):38210-24. (PMID: 26474282) Oncogene. 1997 Jul 10;15(2):143-57. (PMID: 9244350) Mol Cell Biol. 2013 May;33(9):1809-18. (PMID: 23438598) Front Oncol. 2019 Mar 22;9:161. (PMID: 30967995) Biotechnol Lett. 2015 Mar;37(3):523-32. (PMID: 25362258) Saudi J Gastroenterol. 2015 Sep-Oct;21(5):313-9. (PMID: 26458859) Nat Rev Mol Cell Biol. 2013 Aug;14(8):518-28. (PMID: 23877564) Cell Mol Neurobiol. 2015 Nov;35(8):1165-73. (PMID: 26012781) Med Sci Monit. 2020 Jun 08;26:e921200. (PMID: 32508344) Nat Rev Dis Primers. 2021 Jan 21;7(1):6. (PMID: 33479224) Cell Death Dis. 2022 Jan 24;13(1):77. (PMID: 35075115) Mol Biol Cell. 1994 Oct;5(10):1081-92. (PMID: 7865876) Exp Cell Res. 2022 Nov 1;420(1):113335. (PMID: 36084669) Aging (Albany NY). 2021 Aug 25;13(16):20552-20568. (PMID: 34433131) Cell Death Dis. 2017 Oct 26;8(10):e3141. (PMID: 29072692) Mol Ther. 2023 Mar 1;31(3):647-656. (PMID: 36415148) Oncogene. 2021 Sep;40(37):5613-5625. (PMID: 34316028) Cancer Res. 2021 Jun 1;81(11):2874-2887. (PMID: 33771899) Int J Biol Sci. 2022 Jun 25;18(10):4151-4170. (PMID: 35844795) |
| فهرسة مساهمة: | Keywords: E2F2; cancer progression; function; strategy; therapeutic target |
| المشرفين على المادة: | 0 (E2F2 Transcription Factor) 0 (E2F2 protein, human) |
| تواريخ الأحداث: | Date Created: 20240529 Date Completed: 20240529 Latest Revision: 20240530 |
| رمز التحديث: | 20240530 |
| مُعرف محوري في PubMed: | PMC11130366 |
| DOI: | 10.3389/fimmu.2024.1397303 |
| PMID: | 38807594 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1397303 |